Open access
Jul 2026
Structure-Based Design of New Nonpeptidic Covalent Mpro Inhibitors against SARS-CoV-2 and Omicron Variants
The structure-based covalent modifications that generate new nonpeptidic covalent Mpro inhibitors are described that may support the deuterated compound as a new lead for developing anti-SARS-CoV-2 drugs and further reveal the feasibility of using chloroacetyl for structure-based covalent drug design.
Honglei Bao, Ling-Chen Sun, Shi-Lin Gong et al.
· ACS Bio & Med Chem Au · 0 citations